The ongoing challenges in antiviral drug development, exacerbated by the
emergence of novel viruses and the need for rapid therapeutic solutions, have led to a
growing interest in drug repurposing strategies. This chapter explores the dynamic
landscape of drug repurposing in antiviral therapy, focusing on the synergistic
integration of in-silico and target-based approaches. The chapter begins with an
introduction to the significance of drug repurposing in overcoming traditional drug
development hurdles. It delves into in-silico approaches, elucidating the role of
computational methods, molecular docking, and bioinformatics tools in identifying
potential repurposed drugs. Simultaneously, the chapter investigates target-based
approaches, highlighting the importance of target identification, validation, and
screening strategies. Emphasizing the transformative potential of integrating in-silico
and target-based methods, the chapter explores how combined approaches enhance the
efficiency and accuracy of drug repurposing. Challenges, such as ethical
considerations, data quality, and regulatory hurdles, are addressed, providing a
comprehensive overview of the field's complexities. Future perspectives, including the
role of emerging technologies and personalized antiviral therapies, are discussed to
guide further research. The chapter concludes with a detailed analysis of case studies,
focusing on successful examples like Remdesivir and other notable instances, offering
valuable insights and lessons for the future of antiviral drug repurposing. This
comprehensive exploration contributes to the evolving landscape of drug development,
providing a roadmap for researchers and clinicians engaged in the critical endeavour of
combating viral infections through innovative and efficient therapeutic strategies.
Keywords: Antiviral therapy, Drug repurposing, In-silico approaches, Molecular docking, Target identification.
